Figure 1. Estimated Mean Change From Baseline for Gantenerumab, Solanezumab, and Placebo for Cerebrospinal Fluid (CSF) Markers.

Assessment of CSF markers was done for both gantenerumab and solanezumab, respectively, in neurogranin (A and B), soluble triggering receptor expressed on myeloid cells 2 (sTREM2; C and D), chitinase 3–like protein 1 (YKL-40; E and F), and glial fibrillary acidic protein (GFAP; G and H),